The discovery of genetic mapping led to a considerable expansion of medical data knowledge or ‘big data,’ which Foley partner Richard Kaufman suggests can be properly analyzed to improve drug discovery success and reduce the cost of developing a drug. He compares genetic mapping to an exquisite tailoring of one’s personal biology that holds the potential to make drugs developed using this data much more effective and ultimately may lead to better outcomes for patients.
People
Related News
June 2, 2025
In the News
Judith Waltz on CMS Open Payments Case – 'Plea takes compliance to whole new level'
Foley & Lardner LLP partner Judith Waltz commented in the Report on Medicare Compliance article, "In Guilt Plea Over CMS Open Payments Program, Physician Admits to False Statements."
June 2, 2025
In the News
Foley's Nashville Office Opening, Partner Arrivals Highlighted in Legal Press
May 28, 2025
In the News
Cliff Risman Featured on Hospitality Trends – Transactions at 'almost historic levels'
Foley & Lardner LLP partner Cliff Risman is featured in the Law360 Q&A, "Foley Hospitality Leader Talks Deals In Economic Uncertainty."